Conference Day Two
November 21, 2024

8:00 am Check In, Morning Coffee & Light Breakfast

8:55 am Chair’s Opening Remarks

ACCELERATING THE DISCOVERY OF MITOCHONDRIAL BIOMARKERS

9:00 am Uncovering Mitochondrial & Related Pathways for Parkinson’s Disease & Dementia to Discover Biomarkers

  • Daniel Klamer Vice President of Business Development & Scientific Strategy, Anavex

Synopsis

  • Analyzing various methods to discover pharmacodynamic biomarkers for Parkinson’s disease and dementia
  • Identifying specific pathways that could outperform standard markers to overcome the transient nature of metabolic products
  • Leveraging the genetic linkage of Parkinson’s disease and dementia with mitochondrial dysfunction to potentially trace back to the root cause of pathogenesis

9:30 am Fireside Chat: Adopting an Integrated Approach to Measuring Mitochondrial Activity for Validating Biomarkers

  • Krista Casazza Scientific Director, Critical Path Institute
  • Daniel Klamer Vice President of Business Development & Scientific Strategy, Anavex

Synopsis

  • Determining disease-specific biomarkers that can accurately reflect disease progression over time
  • Formulating a shared mechanism to identify biomarkers that can be reliably and non-invasively measured for application across disease indications
  • Interrogating organelle cross-talk to explore non-traditional avenues for biomarker validation

10:15 am Morning Refreshments & Networking

UNLOCKING NOVEL MECHANISMS OF MITOCHONDRIAL TARGETING

11:00 am Pioneering Mito-1041: A Novel siRNA Approach to Modulate Mitochondrial Function for Tissue Selectivity & Specificity

Synopsis

  • Transforming siRNA as a state-of-the-art therapeutic for treating mitochondrial impairment through gene specificity and organ selectivity
  • Highlighting various methods of siRNA delivery to address distinguishing features of organs for restoration of mitochondrial function
  • Creating a roadmap to develop MITO-1041 and related compounds as a novel, safe and effective mitochondrial therapy for treating metabolic-associated liver disease (MASH), acute liver, kidney injury and heart disease

11:30 am Cracking the Code With Mitochondrial Transplant: Reversing the Age of the Immune System

Synopsis

• Unpicking cellular energetics to understand disease indications and drug translation in older patients

• Examining how transplanted mitochondria enhance cellular function and survival for evolutionary advantages

• Discovering Mitrix Bio’s approach to demonstrating age-reversal effects in the immune system of older mice to highlight the potential benefits for elderly human patients

12:00 pm Lunch & Networking

1:00 pm Linking the Convergence of Mito & Lysosomal Quality Control as Key Components of Age-Related Disease Progression

Synopsis

  • Diving into the interplay between mitochondrial and lysosomal quality control in the context of age-related diseases
  • Understanding how disruptions in cellular processes contribute to disease progression and potential therapeutic targets
  • Shedding light on C-Path Institute’s latest research on improving cellular health to combat age-related conditions

TRANSFORMING OUR APPROACH TO MITOCHONDRIAL TREATMENT

1:30 pm Patient Registries: Thinking Beyond the Data Collection for Expanding Therapeutic Avenues

Synopsis

  • Delving into Cure Mito’s global patient registry for Leigh syndrome to uncover what makes it unique
  • Assessing registry data for regulatory use and recognition
  • Evaluating the addition of a new registry: A meaningful contribution or a redundant effort? 

2:00 pm Chair’s Closing Remarks

2:15 pm End of Day Conference